Ireland is the latest candidate to lure the European Medicines Agency should the EMA uproot from London after Britain’s vote to leave the European Union.

Paul Ranson, of global law firm Morgan Lewis’ London Life Science’s Practice, examines how the UK Biopharma must now adapt to a changing landscape.

Shire Plc said the U.S. FDA approved its treatment for patients with primary immunodeficiency, a group of genetic disorders.

Concerted effort by governments, regulators, and industry is rapidly expanding development of new therapies for the more than 7,000 known rare diseases.

Chinese health authorities announced price cuts of up to two-thirds for three expensive drugs.

Roche’s breast cancer drug Perjeta (pertuzumab) has been turned down for use on Britain’s state health service.

Britain’s pharmaceuticals trade body has come out firmly against the country leaving the EU, warning that an exit could put British patients at the back of the line for new medicines.

European Union citizens spend some 24 billion euros ($27.28 billion) on illicit drugs every year, a report said on Tuesday, making it one of the continent’s most profitable activities for organized crime groups. The report, drawn up by Europol and European Union drugs monitoring center EMCDDA, said the advent of new technology such as encrypted […]

Britain’s departure from the European Union would threaten scientific research and jeopardize the 28-nation bloc’s system of drug regulation, the European pharmaceutical industry said on Wednesday.   The declaration is the clearest statement yet on the issue by an industry that includes EU-based players such as Britain’s GlaxoSmithKline and AstraZeneca, France’s Sanofi and Germany’s Bayer. […]

Join TrialScope’s Chief Strategy Officer, Thomas Wicks and Senior Product Specialist, Matt DeFranco, for a timely discussion of how life sciences teams can prepare for these changing requirements.